Coxsackievirus B3 infection and type 1 diabetes development in NOD mice: insulitis determines susceptibility of pancreatic islets to virus infection  by Drescher, Kristen M. et al.
www.elsevier.com/locate/yviroVirology 329 (20Coxsackievirus B3 infection and type 1 diabetes development in NOD
mice: insulitis determines susceptibility of pancreatic islets to
virus infection
Kristen M. Dreschera, Ken Konob, Shubhada Bopegamagec, Steven D. Carsonb, Steven Tracyb,*
aDepartment of Medical Microbiology and Immunology, Creighton University, Omaha, NE 68178, USA
bEnterovirus Research Laboratory, Department of Pathology and Microbiology, University of Nebraska Medical Center,
Omaha, NE 68198-6495, USA
cInstitute for Virology and Preventive Medicine, Bratislava, Slovak Republic
Received 30 March 2004; returned to author for revision 17 April 2004; accepted 3 June 2004
Available online 1 October 2004Abstract
Group B coxsackieviruses (CVB) are believed to trigger some cases of human type 1 diabetes (T1D), although the mechanism by which
this may occur has not been shown. We demonstrated previously that inoculation of young nonobese diabetic (NOD) mice with any of
several different CVB strains reduced T1D incidence. We also observed no evidence of CVB replication within islets of young NOD mice,
suggesting no role for CVB in T1D induction in the NOD mouse model. The failure to observe CVB replication within islets of young NOD
mice has been proposed to be due to interferon expression by insulin-producing beta cells or lack of expression of the CVB receptor CAR.
We found that CAR protein is detectable within islets of young and older NOD mice and that a CVB3 strain, which expresses murine IL-4,
can replicate in islets. Mice inoculated with the IL-4 expressing CVB3 chimeric strain were better protected from T1D onset than were mock-
infected control mice despite intraislet viral replication. Having demonstrated that CVB can replicate in healthy islets of young NOD mice
when the intraislet environment is suitably altered, we asked whether islets in old prediabetic mice were resistant to CVB infection. Unlike
young mice in which insulitis is not yet apparent, older NOD mice demonstrate severe insulitis in all islets. Inoculating older prediabetic mice
with different pathogenic CVB strains caused accelerated T1D onset relative to control mice, a phenomenon that was preceded by detection
of virus within islets. Together, the results suggest a model for resolving conflicting data regarding the role of CVB in human T1D etiology.
D 2004 Elsevier Inc. All rights reserved.
Keywords: Coxsackievirus; Diabetes; InsulitisIntroduction
The group B coxsackieviruses (six serotypes, CVB1-6)
are human enteroviruses [Picornaviridae; Human Entero-
virus B; (Oberste et al., 2004) which have a positive sense
RNA genome that encodes 11 proteins within a single open
reading frame (Tracy et al., 1997). The viral genome is0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.06.049
* Corresponding author. Enterovirus Research Laboratory, Department
of Pathology and Microbiology, University of Nebraska Medical Center,
986495 Nebraska Medical Center, Omaha, NE 68198-6495. Fax: +1 402
559 4077.
E-mail address: stracy@unmc.edu (S. Tracy).packaged in a naked capsid approximately 29 nm in diameter
(Mucklebaur et al., 1995). The primary route of enteroviral
infection is fecal-oral: the initial site of replication is believed
to be within oral lymph nodes and the gut. Viremia occurs
rapidly, spreading virus to secondary sites of infection which
are often involved in disease states such as heart, pancreas,
the central nervous system or skeletal muscle (Melnick,
1996). Group B coxsackieviruses are encountered worldwide
and are established as common causes of diverse benign and
serious human diseases (Melnick, 1996) including myocar-
ditis [reviewed in (Kim et al., 2001, 2002; Martino et al.,
1995)] and pancreatitis (Arnesjo et al., 1976; Gooby-Toedt et
al., 1996; Imrie et al., 1977; Lal et al., 1988; Ramsingh, 1997;04) 381–394
K.M. Drescher et al. / Virology 329 (2004) 381–394382Ursing, 1973). The CVB are also believed to be able to trigger
insulin-dependent type 1 diabetes (T1D) in humans, although
its role in this disease has not been well established
(Baekkeskov and Hansen, 1990; Craighead, 1975; Dippe et
al., 1975; Foulis et al., 1990; Fuchtenbusch et al., 2001;
Gamble, 1976; Hierholzer and Farris, 1974; von Herrath,
2000; Yoon et al., 1979).
The incidence of type 1 (juvenile or insulin-dependent)
diabetes mellitus (T1D) is increasing worldwide (Onkama et
al., 1999). An inability to regulate glucose in diabetic patients
occurs due to autoimmune-mediated loss of insulin-produc-
ing beta cells in the pancreatic islets of Langerhans (Castano
and Eisenbarth, 1990). Complex human genetic (Dorman and
Bunker, 2000; Eisenbarth, 1986; Rotter et al., 1990; Wolf et
al., 1983) plays a significant role in T1D onset but account for
fewer than half of the cases (Barnett et al., 1981; Lo et al.,
1991;Metcalfe et al., 2001; Redondo et al., 2001; Smith et al.,
1998). Most cases of T1D are thus presumed to be a function
of a combination of individual predisposing genetics and
environmental factors, although the identities of putative
environmental triggers remain unknown or largely surmised
(Akerblom et al., 2002; Knip and Akerblom, 1999; von
Herrath, 2000). Viruses, especially CVB, have been repeat-
edly suggested to act as triggers in the development of some
cases of T1D (Jenson and Rpsenburg, 1984; Szopa et al.,
1993; Ylipaasto et al., 2004; Yoon et al., 1979).
The nonobese diabetic (NOD) mouse is a small animal
model of human T1D (Atkinson and Leiter, 1999; Kikutani
and Makino, 1992; Makino et al., 1980). Young (4-week-
old) NOD mice do not exhibit the autoimmune islet
inflammation (insulitis) which is responsible for the
destruction of the beta cells later in life but insulitis is
readily apparent by 8–10 weeks of age. The developing
insulitis and concurrent beta cell killing eventually result in
T1D onset starting to occur by 12–15 weeks of age, 70–
100% of female NOD mice develop T1D by 30–40 weeks
of age (Tisch et al., 1999; Tracy et al., 2002). In a previous
report, it was demonstrated that inoculation of young NOD
mice with any of numerous different strains of CVB3 or
CVB4 resulted in significantly lowered incidences of T1D
over 10 month (Tracy et al., 2002). Despite observations
that CVB replicate to high titers in the murine pancreas
(Tracy et al., 2000, 2002), we observed no evidence of CVB
RNA in NOD mouse pancreatic islets, consistent with the
observations of others (Mena et al., 2000; Vella et al., 1992;
Vuorinen et al., 1989). These results argued against a
mechanism, which invokes direct CVB-induced killing of
pancreatic beta cells in young NOD mice as a mechanism
for triggering T1D onset.
Two mechanisms have been proposed for why pancreatic
islets in young NOD mice remain resistant to CVB infection.
Intraislet production of type 1 interferons alpha/beta (IFNa/
h) inhibits CVB4 replication in islets in vivo (Chehadeh et
al., 2000; Flodstrom et al., 2002). These observations
suggest a local, immune-mediated mechanism by which
CVB could be denied productive replication within pancre-atic islets. The cells which are strongly associated with IFN
production, are the insulin-producing beta cells. The other
hypothetical mechanism by which CVW could be denied
replication within islets is a lack of CAR protein expression,
the receptor for the CVB (Bergelson et al., 1997; Carson et
al., 1997; Tomko et al., 1997). Murine CAR mRNAwas not
detected in murine pancreatic islets by in situ hybridization
analysis (Mena et al., 2000) although others have detected
CAR protein expression using immunohistochemistry (Che-
hadeh et al., 2000). These hypotheses are not mutually
exclusive.
In this report, we sought to reconcile contradictory data
regarding the CVB etiology of human T1D by studying
CVB infections in the NOD mouse host. To begin, we
evaluated hypothetical mechanisms which have been
proposed to account for failure to observe CVB replication
in islets of young mice. Our results demonstrate that CAR
can be detected and that CVB, if expressing the cytokine
IL-4, can also be detected in islets after infection. These
results show that it is possible for CVB to replicate in islets
if the intraislet environment is specifically altered. Having
shown that islets in young mice without insulitis are
resistant to productive CVB replication under normal
circumstances, and reasoning that widespread insulitis
present in older NOD mice as they progress naturally
toward T1D represents an alteration of the islet environ-
ment, we determined whether CVB could replicate in islets
of old, prediabetic mice. We demonstrate that virulent CVB
strains can be detected in the remaining healthy (non-
infiltrated) regions of the islets shortly after infection and
that this is linked to both to rapid T1D onset relative to
control and a high titer of virus in the pancreas tissue.
Together, the results provide a basis for resolving conflict-
ing data regarding the impact of CVB infection upon human
T1D development.Results
Can CVB replicate within islets of young NOD mice?
Although CVB are hypothesized to be triggers of human
T1D, the evidence for this in the related NOD mouse model
is weak. For CVB to trigger T1D in NOD mice, we
reasoned that the virus should be able to replicate within
islets but this has not been observed in young NOD mice
(Mena et al., 2000; Tracy et al., 2002). One hypothesis
suggests that the lack of CAR expression in islets is a barrier
to CVB replication (Mena et al., 2000), while another
proposes that beta cell expression of interferons (IFN)
suppresses intraislet CVB replication (Chehadeh et al.,
2000; Flodstrom et al., 2002). To begin this work, we
evaluated aspects of each hypothesis in an effort to
understand the apparent blockade to CVB replication in
young NOD which are still 2–4 months away from naturally
developing T1D.
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mice and humans (Bergelson, 2003; Bergelson et al., 1998;
Carson, 2001), the lack of CAR expression in islets would be
a compelling argument for failing to observe intraislet CVB
replication in normal mouse islets in vivo (Mena et al.,
2000). Others, however, have reported the detection of CAR
protein in islets using immunohistochemistry (Chehadeh et
al., 2000). Further, in vivo cultured islets support CVB
replication (Roivainen et al., 2000; Szopa et al., 1986;
Toniolo et al., 1982; Vuorinen et al., 1992; Yoon et al.,
1979), while cultivating human islets in culture in the present
of antibodies against CAR prevents CVB infection (Yli-
paasto et al., 2004). We assayed NOD mouse pancreas tissue
immunohistochemically for expression of the CAR protein
with a commercially available antibody (K-20; Santa Cruz
Biotechnology, Santa Cruz, CA) derived against a peptide
sequence completely conserved between mouse and human
CAR. To assess the specificity of the commercial CAR
antibody, we used RD cells, which do not express detectable
CAR, and a line of RD cells that have been engineered to
reexpress human CAR (RD-hCAR). RD-hCAR cells have
been demonstrated by Western blot analysis to express CAR
(Cunningham et al., 2003). We compared results staining
RD-hCAR cells to those obtained staining the parental RD
cell line, which does not express measurable quantities of
CAR. Using the K-20 antibody, positive staining was
observed on RD-hCAR cells (Fig. 1B), while no staining
was observed on RD cells (Fig. 1A).
The K-20 antibody also detected CAR in pancreas
section from young (Fig. 1C) and older NOD mice (Fig.Fig. 1. Detection of CAR protein in NOD mouse and human pancreatic islets of
hCAR) were stained with an antibody against CAR [K-20, Santa Cruz Biotechno
weeks old) NOD mice using the K-20 antibody. Sections from a 14-week-old N
against CAR (K-20) (E), or no primary antibody (F). Arrows follow the same islet
archived human pancreas were stained with the K-20 CAR antibody (G), the human
original magnification, 40 (insert 120); panels C–I, 100.1D). Insulin staining co-localized with CAR staining in
mouse islets (Figs. 1D, E). CAR was not detected in
sections that did not receive primary antibody (Fig. 1F).
Assay of sections from an archival formalin-fixed, paraffin-
embedded human pancreas sample using the K-20 antibody
(Fig. 1G) and a previously characterized, human-specific
CAR antibody, RmCB (Hsu et al., 1988) (Fig. 1H), revealed
a similar localization in islets. No staining was detected in
the absence of a primary antibody (Fig. 1I). The detection of
CAR protein in islets of NOD mouse pancreatic tissue
suggested that the primary block to productive CVB
replication in young NOD mouse islets was not lack of
CAR protein expression.
Interleukin 4 is a key cytokine [reviewed in (Paul, 1991)]
with various effects, among which is the capacity to
modulate IFN [(Gobl and Alm, 1992; Lee et al., 1995;
Varano et al., 2000); reviewed in (Levings and Schrader,
1999)]. Interleukin-4 also suppresses T1D development in
NOD mice (Gallichan et al., 1999; Katz et al., 1995; Mueller
et al., 1996; Wang et al., 1998), an observation that has been
ascribed to downregulation of autoimmune Th1 cells
(Cameron et al., 1997; Fiorentino et al., 1989). Others have
shown INFa/h inhibits CVB4 replication in NOD mouse
islets in vivo (Chehadeh et al., 2000; Flodstrom et al., 2002),
data which offer a different hypothetical mechanism to
account for failure to observe CVB replication in islets of
young NOD mice. We reasoned that a CVB3 strain that
expresses biologically active murine IL-4 [CVB3-mIL4;
(Chapman et al., 2000a)] might sufficiently alter the intraislet
microenvironment to permit virus replication. Young (4Langerhans. Human RD cells and RD cells expressing human CAR (RD-
logy; panels A, B, respectively]. (C) CAR is detected in islets of young (4
OD mouse were stained with an antibody against insulin (D), an antibody
in serial sections (D–F). Sections from a formalin-fixed, paraffin embedded,
-specific RmcB CAR antibody (H), or no primary antibody (I). Panels A, B,
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the control parental CVB3 strain. Productive replication of
CVB3-mIL4 and the parental virus in NOD mouse pancreata
was confirmed by measuring infectious virus titer in total
pancreas tissue as a function of days post-inoculation (p.i.)
(Fig. 2A). Titers of both viruses peaked shortly after
inoculation, then declined, confirming and extending pre-
vious findings for other CVB strains in murine pancreas
tissue (Tracy et al., 2000). The parental strain CVB3/0
replicated approximately 1–2 logs higher titers than CVB3-
mIL4 on day 4 and infectious titers for both viruses were
undetectable by day 8 p.i. consistent with avirulent CVB
strain replication (Tracy et al., 2000). Pancreas sections from
mice killed 4 days p.i. (mock-infected mice, Figs. 2B–D;
CVB3-mIL4 infected mice, Figs. 2E–G) were probed for
CVB protein. Identity of islets was confirmed by staining
with insulin (Fig. 2C) or glucagon (Fig. 2F); the same islets
are shown in hematoxylin and eosin-stained serial sections
(Figs. 2B and E, respectively). Cells that stained well for
viral protein were readily observed in islets of CVB3-mIL4-
inoculated mice (Fig. 2G; the same islet is shown at high
magnification in Fig. 2H). This staining was appreciably
greater than background staining with the same antibody
against enteroviral capsid proteins observed in tissue from
mock-infected mice (Fig. 2D), suggesting that detectable
CVB3-mIL4 replication occurred in islets. These immuno-
histochemical results were further tested using in situ
hybridization (Figs. 2I–K). Pancreas from mock-infected
mice was negative for detection of viral RNA (Fig. 2l; islets
shown with arrows). Viral RNA of the control parental virus
CVB3/0 (which does not produce mIL-4) was not detected in
islets but was apparent in acinar tissue (Fig. 2J). Viral RNA
was detected only in islets of mice previously inoculated
with CVB3-mIL-4 (Fig. 2K). These results demonstrated
that unlike wild-type CVB strains, a CVB3 strain which
expresses biologically active murine IL-4 can replicate
within islets of young NOD mice.
Injection of mice with the double-stranded RNA analog
polyinosinic:polycytosinic acid (poly I:C) strongly stimulates
the innate immune system and induces production of innate
interferons (Biron et al., 1986; Brehm and Kirchner, 1986;
Korngold et al., 1983; Padalko et al., 2004; Pyo et al., 2004).
We reasoned that poly I:C inoculation before CVB3-mIL4Fig. 2. CVB3-mIL4 replicates in NOD mouse pancreas and pancreatic
islets. Titering infectious virus in pancreata of mice previously inoculated
with CVB3-mIL4 or CVB3/0 demonstrate that both viruses replicate in
NOD mouse pancreas tissue (A). Serial pancreas sections from mock-
infected (control) NOD mice (B–D) and CVB3-mIL4-inoculated mice (E–
G) were stained with hematoxylin and eosin (B, E), an antibody against
insulin (C), glucagon (F), or an antibody against enteroviral capsid proteins
(D, G). Panel H shows the same islet as in panel G but at 400
magnification; arrows indicate cells staining positive for virus protein. In
situ hybridization with a DIG-labeled riboprobe against the CVB3 positive
strand RNA was used to probe pancreata of mice inoculated with saline
(controls) (I), CVB3/0 (J) or CVB3-mIL4 (K). Arrows in panels I–K
indicate islets. Original magnification panels B–G, 100; G, 400; panels
I–K, 200.inoculation might also suppress CVB3-mIL4 replication in
pancreas despite the expression of IL-4. To test, this we
inoculated young mice with poly I:C and on the following
day, we inoculated mice with CVB3-mIL4. Mice were killed
at 2 and 4 days post-inoculation with virus. Infectious virus
titer was reduced by 2–3 logs in pancreas tissues of mice
treated with poly I:C versus control mice that were injected
only with saline (Fig. 3A). Pancreas sections were stained for
Fig. 2 (continued).
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Virus protein staining in islets co-localized with insulin
staining. Islets in pancreata of mice which had been
inoculated with poly I:C before CVB3-mIL4 inoculation
showed suppressed staining for viral protein in islets (Fig.
3G) relative to control, CVB3-mIL4-inoculated mice (Fig.
3E). Taken together, these results demonstrate that CVB
replication can occur or be suppressed in islets of normal,
young NOD mice, depending upon the state of the intraislet
microenvironment.
Despite replication of CVB3-mIL4 in islets, fewer mice
develop T1D than controls
Our observation that recombinant CVB3-mIL4 replicated
in islets of young NOD mice permitted testing of the
hypothesis that intraislet CVB replication may trigger T1D
onset. Others have shown that a strain of CVB4 induces
T1D in beta cell expressing suppressor of cytokine signal-ing-1 (SOCS-1) transgenic NOD mice (Flodstrom et al.,
2002), results that have been used to support the hypothesis
that some cases of T1D may be induced by CVB infection
of islets. Groups of NOD mice were inoculated at 4 and 6
weeks of age with CVB3-mIL4 or parental control CVB3/0,
then were maintained to 39 weeks of age. Onset of T1D was
assessed weekly by assaying urine glucose; mice were
considered diabetic when urine glucose levels were z2 g/dL
urine (Tracy et al., 2002). Ninety percent (9/10) of mock-
infected control mice developed T1D before the end of the
experiment (Fig. 4), while only 3/10 (30%) mice inoculated
with CVB3-mIL4 developed T1D during this time; 7 mice
remained healthy. Mice inoculated with the control virus
strain, CVB3/0, fared less well than CVB3-mIL4-inoculated
mice; 6/10 mice (60%) of these mice developed T1D,
although initial onset of T1D was delayed by 7 weeks
relative to control mice. These results demonstrate that
despite intraislet replication of CVB3-mIL4, significantly
fewer mice developed T1D as a consequence of CVB3-
Fig. 2 (continued).
Fig. 3. Inoculation with poly I:C suppresses CVB3-mIL4 replication in
pancreas. Mice (groups of 3) were inoculated with poly I:C or with saline,
then 24 h later inoculated with CVB3-mIL4. (A) Titers of CVB3-mIL4 in
mouse pancreata 2 and 4 days post-inoculation. (B–G) Formalin-fixed,
paraffin-embedded sections from pancreata of mice 2 days post-inoculation
with CVB3-mIL4 were probed immunohistochemically for insulin (panels
B, D, F) and virus (C, E, G) as indicated in the figure. Panels B, C, control
(saline inoculated) mice; panels D, E, saline and CVB3-mIL4 infected
control mice; panels F, G, poly I:C treated and CVB3-mIL4-inoculated
mice. Original magnification, 200.
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intraislet replication of virus must not necessarily be
deleterious to the health of the host.
CVB3 can rapidly accelerate T1D onset in a majority of old,
immediately prediabetic NOD mice
The role of CVB infection as a triggering event for the
onset of human T1D or in murine systems remains unclear
(Coleman et al., 1974; Craighead, 1975; Dippe et al., 1975;
Fuchtenbusch et al., 2001; Gamble, 1976; Hierholzer and
Farris, 1974; Nairn et al., 1999; Oldstone et al., 1990;
Ramsingh et al., 1997; Takei et al., 1992; Tracy et al., 2002;
Wagenknecht et al., 1991). While inoculation of 4-week-old
NOD mice with CVB prevents T1D onset in the majority of
mice relative to no treatment (Tracy et al., 2002), there is no
observable insulitis at this age. This soon changes, by 8
weeks of age, insulitis is consistently detected in pancreatic
islets of NOD mice. Notably, inoculation of mice at 8 weeksof age (in contrast to 4-week-old mice) with CVB has been
observed to cause accelerated T1D onset in some mice
relative to mock-infected control mice (Serreze et al., 2000;
Tracy et al., 2002). Accelerated, CVB-triggered T1D onset
in 8-week-old mice is related to the extent of insulitis at the
time of inoculation: accelerated T1D onset is due to an
expanding population of autoimmune lymphocytes (Serreze
et al., 2000). However, if CVB infection triggers accelerated
T1D onset in NOD mice only when insulitis has reached a
critical threshold, then few mice at 8 weeks of age meet this
Fig. 4. Inoculation of young NOD mice with CVB3-mIL4 suppresses T1D
incidence. Groups of 10 NOD mice were inoculated with the CVB3 strains
shown in the figure; mock-infected mice were inoculated with saline. T1D
onset was ascertained by measuring urine glucose content. Surviving mice
were killed at 39 weeks of age.
Fig. 5. Impact on T1D development of inoculating older, prediabetic mice
with different CVB3 strains. Groups of 10 NOD mice were inoculated at 15
weeks (A) or 17 weeks of age (B) with strains of CVB3 that differed by
virulence phenotype. Control mice were mock infected with saline. T1D
onset ascertained by measuring urine glucose content. Surviving mice were
killed at 33 weeks (A) or 36 weeks of age (B).
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age, with widespread insulitis and T1D beginning to occur,
every NOD mouse can be considered to be immediately
prediabetic. We reasoned that older, immediately prediabetic
mice would be at risk for accelerated T1D onset following
CVB inoculation based on the hypothesis that the extent of
lymphocytic infiltration in islets is linked to accelerated
T1D onset. There would also be significantly fewer intact
beta cells in the prediabetic mice relative to healthy, younger
mice. Widespread insulitis and decreased beta cell popula-
tions might constitute a significant islet microenvironment
alteration, analogous to that obtained in young SOCS-1
transgenic mice (Flodstrom et al., 2002) or in young mice
inoculated with CVB3-mIL4.
To determine the effect of CVB replication upon T1D
onset and incidence in older NOD mice, we inoculated
NOD mice (15 weeks of age) with CVB3/28, a virulent
strain, or CVB3/GA, an avirulent strain (Tracy et al., 2000,
2002). Diabetes developed in 7/10 mice (70%) within 2
weeks of inoculation with CVB3/28 (Fig. 5A), in contrast to
long-term protection afforded the majority of mice when
inoculated at 4 weeks of age (Tracy et al., 2002). The T1D
incidence in mock-infected mice did not reach 70% for
another 9 weeks. Inoculation with CVB3/GA, however,
delayed T1D onset by 5 weeks relative to mock-infected
(control) mice but thereafter 70% of mice developed T1D
by 30 weeks of age. Stained pancreas sections revealed
typical CVB3/28-induced widespread pancreatitis while
CVB3/GA induced no pancreatitis (data not shown),
consistent with previous results (Tracy et al., 2002). These
results demonstrated that a CVB infection can dramatically
impact T1D development in a population of immediately
prediabetic, older NOD mice. Further, the outcome of the
infection was significantly different, either adverse or
temporarily beneficial, as an apparent function of the viral
virulence phenotype.
A second experiment tested the hypothesis that the
CVB3 virulence phenotype can affect timing of initial T1D
onset in older, prediabetic mice following inoculation. NODmice (17 weeks of age) were inoculated with CVB3/AS, a
virulent strain (Tracy et al., 2000, 2002). CVB3/CO, a strain
which induces variable pancreatitis (Tracy et al., 2000) or
the avirulent strains, CVB3/GA or CVB3/49. Virulent
CVB3/AS inoculation greatly accelerated T1D development
relative to mock-infected control mice; 70% of mice (7/10)
were diabetic within 3 weeks of inoculation (Fig. 5B) versus
less than 30% of control mice, consistent with and
confirming previous results using CVB3/28 (Fig. 5A).
CVB3/GA and CVB3/49 each slowed the rate of T1D
onset relative to mock-infected control mice; both groups
developed T1D incidences of 40% by the time the experi-
ment was ended. CVB3/CO induced accelerated T1D in two
mice relative to the control group but thereafter, no
significant difference was observed relative to control mice
in the rate of T1D development; the final T1D incidence
was 70% in this group (Fig. 5B). These results demonstrated
that the outcome of inoculating older, immediately predia-
betic NOD mice with different CVB3 strains is dependent
upon the viral virulence phenotype: virulent CVB3 strains
significantly accelerate T1D onset in a majority of mice,
whereas avirulent CVB3 strains initially delay T1D onset
relative to mock-infected control mice. These results differ
sharply from those obtained using 4-week-old NOD mice in
K.M. Drescher et al. / Virology 329 (2004) 381–394388which insulitis is not apparent inoculated with the same
CVB3 strains (Tracy et al., 2002): inoculation of young
mice with any CVB strain significantly reduced the change
of T1D development, with virulent virus strains being the
most protective.
Virulent CVB3 is detected in pancreatic islets of
immediately prediabetic NOD mice
Because inoculation with virulent CVB3 strains greatly
accelerated T1D onset in older and immediately prediabetic
mice, we reasoned that virus replication within cells in the
islets may be linked to the rapid onset of T1D. To test
whether CVB were detectable in islets of old mice following
inoculation, we assayed pancreas section of 17-week-old
NOD mice killed 4 days after inoculation with different
CVB strains for evidence of virus in islets. CVB protein was
detected by immunohistochemistry in islets of mice
inoculated with virulent strains indicating viral replication,
in marked contrast to the results in young mice inoculated
with either of two avirulent strains was indistinguishable
from control mice. Fig. 6 displays typical results using
sections from pancreata of mice inoculated with CVB3/28
(Figs. 6A–D), CVB3/CO (Figs. 6E–H), CVB3/49 (Figs. 6I,
J), or from mock-infected control mice (Figs. 6K, L). Insulin
staining identified islets as well as remaining functional islet
tissue (Figs. 6B, F, I, K) in the presence of advanced
insulitis which is shown in hematoxylin and eosin-stained
sections (Figs. 6A, E). Panel I demonstrates a highly
inflamed islet; minimal insulin staining was observed.Fig. 6. CVB3 can be detected within islets of older, prediabetic NOD mice. Mice w
(panels E–H), CVB3/49 (panels I, J) or saline (mock-infected; panels K, L). Serial
antibody against insulin (panels B, F, I, K), an antibody against CAR (K-20; panel
arrows indicate acinar tissue staining for viral proteins (panels D, H); small arro
magnification, panels A–H, 400; panels I–L, 200.Staining for viral protein was positive in islets (thin arrows)
and in acinar tissues (large arrows) of mice previously
inoculated with virulent CVB3/28 (Fig. 6D). Detection of
virus protein in islets (Fig. 6H) of mice inoculated with less
virulent CVB3/CO was less clearly defined than that
observed with virulent strains, but trended higher than
either islets from mice inoculated with avirulent strains like
CVB3/49 (Fig. 6J) or mock-infected control mice (Fig. 6L).
In addition, pancreatic acinar tissue in CVB3/CO-inoculated
mice was usually positive for viral protein detection (Fig.
6H, large arrow), whereas acinar tissue from mice inocu-
lated with virulent strains was consistently positive for the
detection of viral protein (Fig. 6D). These results showed
that replication of virulent CVB3 strains occurs in the
remaining healthy areas of islets in older prediabetic mice
before the rapid T1D onset which occurs within 2–3 weeks
of virus inoculation.
Detection of CVB3 in islets of prediabetic mice, which is
related to virulence phenotype of the virus, did not explain
why less virulent or avirulent strains were not as readily
detected in islets. Having previously established that
virulent CVB3 strains replicate to higher titers than avirulent
strains in pancreas tissue of young NOD and other strains of
mice (Tracy et al., 2000, 2002), we determined whether
CVB3 strains similarly generate different titers as a function
of virulence phenotype in older NOD mice. Infectious titers
in pancreata of 15-week-old mice previously inoculated
with one of 5 different strains of CVB3 were determined 4
days post-inoculation, a time when virus titer peaks in the
pacreas (Tracy et al., 2000; Fig. 2A). Highly virulent strainsere killed 4 days post-inoculation with CVB3/28 (panels A–D), CVB3/CO
pancreas sections were stained with hematoxylin and eosin (panels A, E) an
s C, G), or an antibody against enterovirus capsid protein (D, H, J, L). Large
ws indicates positive staining for virus protein in islet (panel D). Original
Fig. 7. Infectious titers of different CVB3 strains in pancreata of older,
prediabetic mice. Mice (groups of 3) were inoculated at 25 weeks of age
with one of five strains of CVB3 shown in the figure. Mice were killed
4 days later and infectious titers in pancreas tissue determined. The mean
titers are shown with bars denoting standard deviation.
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higher than the avirulent strains, CVB3/GA and CVB3/49
(Fig. 7). Moderately virulent CVB3/CO replicated to 1–2
logs higher in titer than the avirulent strains. This variation
in titer was similar to that observed earlier in younger mice,
providing a rational to explain why only virulent strains
induced rapid T1D onset in the majority of older mice.Discussion
Human T1D etiology is a complex problem and a poorly
understood combination of individual genetic factors,
putative environmental triggers [reviewed in (Atkinson
and Maclaren, 1994; Bach, 1994; Baekkeskov and Hansen,
1990; Barnett et al., 1981; Bertrera et al., 1999; Blom et al.,
1989; 1991; Chowdhury et al., 1999; von Herrath, 2000).
The NOD mouse permits the study of T1D in a small animal
model which although not a perfect model of human T1D,
recapitulates many aspects of human T1D (Atkinson and
Leiter, 1999). Experimental exposure of NOD mice to
diverse agents, either infectious or chemical, can variably
suppress T1D incidence (Atkinson and Leiter, 1999); this
list also includes several murine viruses. Previous results
(Tracy et al., 2002) were consistent with these observations:
inoculation of young NOD mice with any of several
phenotypically diverse and genetically distinct CVB3 or
CVB4 strains lowered T1D incidences relative to mock-
infected mice. However, our observations were unique in
that of all the viral agents studied in the NOD mouse model,
only the CVB are commonly encountered human viruses
worldwide and are implicated as causes, not inhibitors, of
T1D induction in humans. Despite the protective effect by
CVB demonstrated in this initial paper, we did not address
reports which strongly suggest that CVB infections are
associated with some cases of human T1D onset [for
example, (Andreoletti et al., 1997; Champsaur et al., 1980;
Chehadeh et al., 2000; Clements et al., 1995; Hyoty et al.,
1998; Ylipaasto et al., 2004)]. We explored this further bydeveloping a model in older mice to text the hypothesis that
CVB can trigger T1D.
We began by assuming that CVB-induced destruction or
impairment of the insulin-producing pancreatic beta cells
was key to the hypothesis that CVB can induce T1D.
Previous results demonstrated a remarkable CVB-induced
protein of young NOD mice from T1D onset and no
evidence for productive CVB3 replication in pancreatic
islets of young mice despite high viral titers in pancreata
within 1–2 days post-inoculation (Tracy et al., 2002). This
argued against a deleterious role for the viruses in promoting
T1D onset in the T1D model using young NOD mice. From
the work of others, it appeared likely that CVB are unable
naturally to infect islets in young NOD mice due to one or
more factors, described either as limited or no CAR
expression (Mena et al., 2000) and/or the production of
IFNa/h by pancreatic islet beta cells (Chehadeh et al., 2000;
Flodstrom et al., 2002).
We detected CAR protein murine islets with a commer-
cially available CAR antibody, the specificity which was
demonstrated by the detection of RD cells engineered to
express human CAR (Cunningham et al., 2003). CAR was
also detected in human islets using this antibody and a
previously characterized human CAR-specific antibody
(Hsu et al., 1988). These results confirmed reports which
demonstrate that CVB can replicate in cultured islets and
can be inhibited by the presence of anti-CAR antibody
(Roivainen et al., 2000; Szopa et al., 1986; Toniolo et al.,
1982; Vuorinen et al., 1992; Yoon et al., 1979). We cannot
explain the disparity between these and others’ results
(Chehadeh et al., 2000) and those reported previously
(Mena et al., 2000) in which CAR mRNA in murine islets
was not detected using in situ hybridization, although it
cannot be excluded that CAR mRNA may be transcribed in
islets at levels below the limits of the in situ hybridization
system employed.
Another hypothesis to account for the inability of CVB to
replicate in islets of young mice which has been proposed
by two different groups is that intraislet IFN expression
inhibits CVB replication in mouse islets (Chehadeh et al.,
2000; Flodstrom et al., 2002). Interleukin-4 is an anti-
inflammatory cytokine with various effects upon the
immune system [(Gobl and Alm, 1992; Lee et al., 1995;
Varano et al., 2000); reviewed in (Levings and Schrader,
1999)]. Interleukin-4 additionally suppresses T1D develop-
ment in NOD mice (Gallichan et al., 1999; Katz et al., 1995;
Mueller et al., 1996; Wang et al., 1998), most likely due to
downregulating pathogenic autoimmune Th1 cells
(Cameron et al., 1997; Fiorentino et al., 1989). Using a
CVB3 strain that expresses biologically active murine IL-4
(Chapman et al., 2000a), we observed CVB3-mIL4 in islets
of young NOD mice shortly after inoculation, mice parental
CVB3 was not detected in islets. We also showed that
CVB3-mIL4 titers fall in the pancreata of young mice
treated before infection with the potent inducer of innate
immune system, poly I:C (Biron et al., 1986; Brehm and
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2004b; Pyo et al., 2004). Thus, the simple expression of
murine IL-4 by CVB3 facilitated productive CVB repli-
cation in islets; this occurred without resorting to
approaches such as generating transgenic mice (Flodstrom
et al., 2002), which has the potential of inducing other
unknown effects due either to the genetic manipulation and/
or the global loss of these IFN (Gerlai, 1996; Steinman,
1997; Wolfer et al., 2002). Further work is required to
clarify the mechanism by which CVB3-expressed IL-4 can
replicate within islets.
The foregoing results showed CAR expression occurred
within islets of young NOD mice, data that were mecha-
nistically confirmed by the demonstration that CVB3-mIL4
replicated in mouse islets. These data showed that as long as
the intraislet environment was suitably altered, replication of
CVB in young NOD mice could occur. We used this finding
to ask what impact CVB3-mIL4 replication within islets of
young mice would have upon T1D onset. We observed that
fewer of these NOD mice developed T1D compared to
control groups, contrary to a simple etiologic hypothesis of
CVB-induced T1D that invokes CVB-induced loss of islet
beta cells. This finding suggests that CVB infections of
pancreatic islets may occur in some islets of young mice, is
rapidly cleared from the mouse by the innate and early
adaptive immune responses before significant damage
occurs, thus failing to trigger accelerated T1D. This is
supported by results, which demonstrate that pancreatic
viral titers peak at 4 days p.i. and are no longer detectable by
day 8, results that are similar to those which show that
avirulent CVB3 strains are more rapidly cleared than
virulent strains (Tracy et al., 2000). Rapid clearance of
CVB3-mIL4 from the pancreas as a whole, coupled with
lower titers of the recombinant virus, would help to
minimize islet damage. It has also been demonstrated that
induction of a Th2 response in NOD mice by IL-4 protects
mice from T1D (Cameron et al., 1997; Gallichan et al.,
1999); we speculate that a similar mechanism, previously
demonstrated following inoculation of CVB3-mIL4 in a
different strain of mouse (Chapman et al., 2000a), may at
least partially account for the lower T1D incidence in
CVB3-mIL4-inoculated NOD mice.
The rapidity with which T1D induction occurred in older,
immediately prediabetic NOD mice following inoculation
with virulent CVB3 suggests significant damage occurs as a
function of the intraislet virus infection. Immunohistochem-
ical staining revealed that CVB replicates only in unin-
volved sections of islets, the same regions in which insulin
is expressed. Similar accelerated onset results have been
observed in a minority of 8-week-old NOD mice inoculated
with CVB (Serreze et al., 2000; Tracy et al., 2002). Those
observations indicate that CVB infections trigger rapid T1D
onset when a sufficient population of autoimmune lympho-
cytes has been achieved (Serreze et al., 2000). Because
CVB triggers T1D only in a few mice at 8 weeks of age, it
may be assumed that insulitis in those few diabetic mice wassignificant, much as is observed later at 12–15 weeks of age.
Thus, the CVB-induced rapid T1D onset, which can occur
sporadically in 8-week-old mice, occurs in nearly every
mouse at about 15–17 weeks of age following with a
pathogenic CVB strain. In contrast to results in 4-week-old
mice with little or no insulitis, and in which the inoculation
of any CVB strain provided protection from T1D onset
(Tracy et al., 2002), the impact of CVB infections in older
prediabetic NOD mice with widespread insulitis can be
understood as manifesting one of three outcomes: immedi-
ately deleterious due to infection by highly virulent strains,
temporarily beneficial when infected by avirulent strains, or
without noticeable impact relative to the control (mock-
infected) mice when infected by pancreovirulent strains.
Results in this report demonstrate that CVB can replicate
in islets of NOD mice when the intraislet environment has
been altered to be different from that found in healthy young
NOD mice. Others had shown that this can attained in
transgenic mice (Flodstrom et al., 2002) or by cultivating
islets in vitro in the presence of anti-IFN alpha neutralizing
antibody (Chehadeh et al., 2000). Our results are consistent
with those reports which hypothesize that intraislet and/or
beta cell IFN production is a barrier to CVB replication in
islets of young NOD mice (Chehadeh et al., 2000;
Flodstrom et al., 2002). By extrapolating our results to
humans, our findings offer a plausible explanation for
reports of sudden T1D onset during or following human
CVB circulation [for example, (Andreoletti et al., 1997;
Helfand et al., 1995; Nairn et al., 1999)]. We theorize that
two criteria, defined here in the NOD mouse model, would
have been met in such cases of sudden T1D onset: (1) the
infecting CVB strain would have been a pathogenic one,
similar to the strains CVB3/AS and CVB3/28 used in this
report [and as described elsewhere; (Lee et al., 1997; Tracy
et al., 2000)] and (2) the affected individuals would have
been immediately prediabetic with extensive insulitis
present before the virus infection. Although the latter
condition is effectively impossible to verify in humans
due to ethical and clinical difficulties, it is possible to test
whether a CVB strain is pathogenic. If the specific CVB
strain were not available, one might less rigorously test the
hypothesis by assaying those strains which circulated in the
local population at the time of T1D onset. Our results also
suggest an explanation for why the great majority of CVB
infections are not associated with sudden onset T1D.
Infection of prediabetic NOD mice with less virulent strains
either had no impact on the rate with which T1D developed
in the mice relative to controls, or T1D onset was delayed
well past the time of the acute infection. In either case, were
a similar condition to obtain in humans, it would be
extremely difficult to link subclinical infections with
subsequent T1D onset. The rates of T1D onset in older
NOD observed inoculation with avirulent or less virulent
CVB strains suggest that an etiologic scenario of a hit-and-
run infection (Ramsingh et al., 1997) followed by CVB-
initiated T1D onset at a much later time may be unlikely.
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interplay between NOD mouse host immunity and CVB
genetics which can result either in what appears to be
lifelong protection from the T1D onset. We believe that
defining both the CVB-induced protective mechanism in
mice and the molecular CVB genetics which mediate its
efficiency will be crucial to better understanding the roles of
virus infection in T1D etiology as modeled in NOD mice.
Although the NOD mouse T1D model is not a perfect
reflection of the human disease and results obtained using it
must be carefully weighed, the manner in which these two
factors interact in NOD mice may help to reconcile often
contradictory reports regarding a role for CVB infections in
human T1D etiology while simultaneously suggesting an
approach for a vaccine strategy. These results may also hint
at an outline of a general mechanism which could apply to
the etiology of other autoimmune diseases in which viral
infections have been implicated as a factor in their
development such as multiple sclerosis (Soldan and
Jacobson, 2001; Theil et al., 2001).Methods
Viruses and cells
All strains of CVB3 and CVB4 used in these experi-
ments, their propagation in and titering on HeLa cell
monolayers, have been described previously (Chapman et
al., 2000a, 2000b; Lee et al., 1997; Tracy et al., 2002). The
strain CVB3/46 expresses biologically active murine IL-4
and has been described (Chapman et al., 2000a); it is
termed CVB3-mIL4 in this report for ease of reference.
RNA preparations from the CVB3-mIL4 stock used here
were assayed by direct RT-PCR-mediated sequence anal-
ysis before use to verify the presence of the murine IL-4
encoding insert (data not shown). CVB3/49 (Chapman et
al., 2000b) is a chimeric strain in which the 5V NTR of
CVB3 was replaced with that from poliovirus type 1
(Semler et al., 1986); this strain is avirulent in mice,
causing neither pancreatitis nor myocarditis. RD (human
rhabdomyosarcoma) cells were obtained from the ATCC
(Manassas, VA). The creation of RD cells that express
human CAR (Rh-hCAR) have been described (Cunning-
ham et al., 2003).
Mice
Nonobese diabetic (NOD) female mice were purchased
from Taconic (Germantown, PA) at 4 weeks of age and aged
as necessary. Mice were housed five per cage for as
described previously (Tracy et al., 2002). Mice were
inoculated intraperitoneally (i.p.) with 0.1 mL containing
5  105 TCID50 of virus, diluted in sterile 100 mM NaCl.
Poly I:C treatment of mice was by inoculation of 0.1 mL
saline containing 100 Ag poly I:C (Sigma, St. Louis MO)which had been sterilized by twice passaging through 0.2
micron syringe tip filters; control mice received saline alone.
Twenty-four hours later, mice were inoculated with 5  105
TCID50 CVB3-mIL4 in saline. To monitor T1D onset, mice
were assayed weekly for glucose in urine using commercial
dipsticks (Diastix; Bayer, Elkhart, IN) as described (Tracy et
al., 2002) starting at 8 weeks of age. Mice with glucose at 2
g/dL urine were considered diabetic. Pancreata were excised
after death. Pancreas was frozen under dry ice for later titer
determination or fixed in buffered formalin before embed-
ding in paraffin for sectioning.
Infectious virus titers in pancreas
Infectious titers in pancreatic tissues were determined on
HeLa cell monolayers (Tracy et al., 2002). Briefly, weighed,
frozen pancreata were homogenized in complete tissue
culture medium. After freezing and thawing, the centrifu-
gally cleared supernatants were assayed for the presence of
infectious virus. Titers were expressed as TCID50/g pancreas
tissue.
In situ hybridization
Detection of CVB3 RNA by in situ hybridization was
carried out as described, (Tracy et al., 2002). Briefly, a
digoxygenin (DIG) labeled riboprobe complementary to the
CVB3 positive strand 5V non-translated region was synthe-
sized in a runoff T7 DNA polymerase reaction. Hybrid-
ization was carried out on deparaffinized sections of murine
pancreas. Sections were lightly counterstained with nuclear
fast red.
Immunohistochemistry
Immunohistochemical detection of insulin, glucagon,
coxsackievirus adenovirus receptor (CAR), and enteroviral
protein was carried out essentially as described (Tracy et al.,
2002) with modifications. Pancreas sections were cut at 6-
Am thickness from formalin-fixed, paraffin-embedded tis-
sue. For detection of CAR on RD cells, cells [RD or RD-
hCAR; (Cunningham et al., 2003)] were plated on chamber
slides the day before fixing in cold acetone for 30 s,
followed by air drying. For detection of CAR or CVB
protein, pancreas sections were deparaffinized, hydrated
through an ethanol series, immersed in 10 mM sodium
citrate buffer (pH 6), and steamed in a vegetable steamer
(Black and Decker, Towson, MD) for 30 min. Slides were
cooled to room temperature and washed in PBS (phosphate-
buffered saline). For detection of CAR on RD and RD-
hCAR cultures, slides were immersed in 0.2% hydrogen
peroxide in methanol for 5 min at room temperature
following binding of primary antibody. Enteroviral protein
was detected using a mouse monoclonal antibody (1:200;
Dako, Carpinteria, CA), insulin with a guinea pig antibody
to pig insulin (1:200; Sigma), and glucagon with a rabbit
K.M. Drescher et al. / Virology 329 (2004) 381–394392antibody (1:200; Chemicon, Temecula, CA. The following
biotinylated secondary antibodies were used: sheep anti-
mouse F’ab2 fragment (Chemicon), goat anti-guinea pig
IgG (Vector Labs, Burlingame CA), goat anti-rabbit IgG
(Vector), and rabbit anti-goat IgG (Vector). CAR was
detected with a goat polyclonal antibody (K-20; 1:200;
Santa Cruz Biotechnology) or on human section using the
antibody RmcB (Hsu et al., 1988). According to Santa Cruz
Biotechnology, which did not divulge the peptide sequence
against which the K-20 antibody was raised, the peptide
sequence is within a region that is conserved between
human and mouse CAR sequences. The extracellular protein
primary structure of murine and human CAR differ by 10%
and are more than 95% conserved in the intracellular
domains (Bergelson et al., 1998). Following washes in PBS,
slides were incubated with ABC Elite (Vector) and
developed with the DAB substrate kit (Vector). Slides were
lightly counterstained with hematoxylin, rinsed in saturated
lithium carbonate in water for 10 s at room temperature, and
rinsed in water. Slides were dehydrated and coverslipped
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